Khorana Risk Score for Venous Thromboembolism in Cancer Patients
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
The Khorana Risk Score for Venous Thromboembolism in Cancer Patients calculates predicting VTE risk for cancer patients depending on cancer type and other factors. Key inputs include cancer type. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Predicts VTE risk for cancer patients depending on cancer type and other factors. This validated risk assessment tool helps identify cancer patients at high risk for venous thromboembolism who may benefit from thromboprophylaxis during chemotherapy treatment.
Clinical Indication
The Khorana Risk Score for Venous Thromboembolism in Cancer Patients is indicated for bedside clinical practice to support Predicts VTE risk for cancer patients depending on cancer type and other factors. This validated risk assessment tool helps identify cancer patients at high risk for venous thromboembolism who may benefit from thromboprophylaxis during chemotherapy treatment.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care. Clinical exclusion: Do NOT use in patients with brain tumors or multiple myeloma.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Limited sensitivity: only 23.4% of patients who develop VTE are classified as high risk.
Cancer type (very high-risk: 2 pts, high-risk: 1 pt, standard: 0 pts) + platelet count ≥350 (1 pt) + Hgb <10 or EPO use (1 pt) + leukocyte count >11 (1 pt) + BMI ≥35 (1 pt)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| cancer_type | string | Yes | Type of primary cancer. Very high-risk cancers (stomach, pancreas) score 2 points; high-risk cancers (lung, lymphoma, gynecologic, bladder, testicular) score 1 point; other cancers score 0 points |
| platelet_count_elevated | string | Yes | Pre-chemotherapy platelet count ≥350×10⁹/L (≥350,000/μL). Scores 1 point if yes |
| hemoglobin_low_or_epo | string | Yes | Hemoglobin level <10 g/dL or using red blood cell growth factors (erythropoietin, darbepoetin). Scores 1 point if yes |
| leukocyte_count_elevated | string | Yes | Pre-chemotherapy leukocyte count >11×10⁹/L (>11,000/μL). Scores 1 point if yes |
| bmi_elevated | string | Yes | Body mass index ≥35 kg/m². Scores 1 point if yes |
Evidence-Based References (EBM)
- Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated venous thromboembolism. Blood. 2008;111(10):4902-7.
- Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-82.
- Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291-2.
- Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277-1287.